1
/
of
1
Bezom (Bortezomib)
Bezom (Bortezomib)
Regular price
₱24,000.00 PHP
Regular price
Sale price
₱24,000.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Bortezomib (Bezom) is a potent proteasome inhibitor and antineoplastic agent used in the treatment of multiple myeloma and mantle cell lymphoma. This targeted cancer therapy works by blocking the 26S proteasome, an enzyme complex essential for protein degradation within cells. By inhibiting proteasomal function, bortezomib disrupts cancer cell cycle progression and induces apoptosis, particularly in rapidly dividing malignant cells, making it a cornerstone therapy in modern oncology.
Bortezomib is FDA-approved for multiple myeloma, both in newly diagnosed patients and those with relapsed or refractory disease, as well as for mantle cell lymphoma in treatment-experienced patients. It is frequently incorporated into combination chemotherapy regimens alongside agents such as dexamethasone, cyclophosphamide, lenalidomide, and rituximab to enhance therapeutic efficacy and improve patient outcomes. The synergistic effects of these combinations have demonstrated superior response rates and survival benefits across various hematologic malignancies.
The medication is contraindicated in patients with known hypersensitivity to bortezomib, boron, or mannitol. Pregnancy and breastfeeding are absolute contraindications due to teratogenic effects and potential harm to the developing fetus or nursing infant. Caution is advised in patients with severe hepatic impairment, pre-existing peripheral neuropathy, or significant pulmonary or cardiac disease, as bortezomib may exacerbate these conditions.
Dosing is individualized and determined by your oncologist based on disease stage, prior treatment history, organ function, and overall clinical status. Regular hematologic and metabolic monitoring is essential during treatment. This medicine must only be used under direct medical supervision and prescription from a licensed healthcare provider.
Bortezomib is FDA-approved for multiple myeloma, both in newly diagnosed patients and those with relapsed or refractory disease, as well as for mantle cell lymphoma in treatment-experienced patients. It is frequently incorporated into combination chemotherapy regimens alongside agents such as dexamethasone, cyclophosphamide, lenalidomide, and rituximab to enhance therapeutic efficacy and improve patient outcomes. The synergistic effects of these combinations have demonstrated superior response rates and survival benefits across various hematologic malignancies.
The medication is contraindicated in patients with known hypersensitivity to bortezomib, boron, or mannitol. Pregnancy and breastfeeding are absolute contraindications due to teratogenic effects and potential harm to the developing fetus or nursing infant. Caution is advised in patients with severe hepatic impairment, pre-existing peripheral neuropathy, or significant pulmonary or cardiac disease, as bortezomib may exacerbate these conditions.
Dosing is individualized and determined by your oncologist based on disease stage, prior treatment history, organ function, and overall clinical status. Regular hematologic and metabolic monitoring is essential during treatment. This medicine must only be used under direct medical supervision and prescription from a licensed healthcare provider.
Share
